Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DSM closes citric acid plant

This article was originally published in The Tan Sheet

Executive Summary

The Netherlands-based life and material sciences firm will close its Wuxi, China citric acid manufacturing plant by the first quarter of 2009, DSM announces Aug. 15. The closure comes after a request from the local government to relocate the plant because its current location is slated for urban development, DSM says. The firm does not expect to incur a loss due to the closing of the plant since the Wuxi government compensated DSM. The company decided not to rebuild the plant, but to relocate operations to its Tienen, Belgium site. ... Invests in Provexis: DSM Venturing acquires a 29.3 percent equity stake in Provexis, a development and licensing firm for functional food ingredients, medical foods and supplements. "The investment is in line with DSM's strategy to further expand in ingredients for functional food and dietary supplements focusing on, for example, cardiovascular and digestive health, two areas also addressed by Provexis," DSM says in an Aug. 27 release. Provexis' lead product is FruitFlow, a biotactive from tomato extract that improves blood flow for cardiovascular health, DSM says. Several large food manufacturers, including Unilever, have expressed interest in the ingredient, the firm says

You may also be interested in...

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts